EPAS1 and kidney cancer: We found that the drug combination of rapamycin and AICAR had a strong additive effect in decreasing cell proliferation, increasing cell apoptosis, and abolishing Akt and HIF2α expression in RCC cell lines and primary ccRCC cells isolated from kidney cancer patient.